$26.38
-0.48-1.79%
At close: Aug 13, 5:00 PM EST
$26.38
N/A
After Hours: 4:00 PM EST
Ultragenyx Pharmaceutical Inc
RARENASDAQ
Ultragenyx Pharmaceutical Earnings & Forecasts
Ultragenyx Pharmaceutical (RARE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Ultragenyx Pharmaceutical Guidance
Ultragenyx Pharmaceutical (RARE) last issued guidance on August 4, 2026 for fiscal year 2026. The company guided revenue in the range of $730M - $760M for the period.
Compared to prior guidance, Ultragenyx Pharmaceutical maintained its revenue forecast from a prior range of $730M - $760M.
Ultragenyx Pharmaceutical has issued 21 guidance updates between February 16, 2023 and August 4, 2026. During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.16 | $-1.48 | $-1.18 | $-1.22 |
| Actual | $-0.90 | $-1.84 | $-1.29 | $-1.81 |
| Surprise | +22.4% | -24.3% | -9.32% | -48.4% |
| Revenue | ||||
| Estimate | $182.5M | $159.0M | $202.3M | $167.1M |
| Actual | $214.0M | $136.0M | $207.0M | $159.9M |
| Surprise | +17.2% | -14.4% | +2.33% | -4.28% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.66 | $-0.82 | $-0.46 | $-0.05 |
| Revenue | ||||
| Consensus | $184.8M | $226.2M | — | — |
